{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:47:55Z","timestamp":1793998075317,"version":"4.8.0"},"reference-count":224,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274323"],"award-info":[{"award-number":["82274323"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01982-8","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:20:05Z","timestamp":1765516805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of PD\u20111\/PD\u2011L1 axis in liver diseases"],"prefix":"10.1007","volume":"26","author":[{"given":"Zijian","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanglan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"6","key":"1982_CR1","doi-asserted-by":"publisher","first-page":"e99574","DOI":"10.1371\/journal.pone.0099574","volume":"9","author":"J Kaczmarek","year":"2014","unstructured":"Kaczmarek J, Homsi Y, van \u00dc\u00fcm J, Metzger C, Knolle PA, Kolanus W, et al. Liver sinusoidal endothelial cell-mediated CD8 t cell priming depends on co-inhibitory signal integration over time. PLoS ONE. 2014;9(6):e99574. https:\/\/doi.org\/10.1371\/journal.pone.0099574.","journal-title":"PLoS ONE"},{"issue":"1","key":"1982_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jhep.2012.09.008","volume":"58","author":"A Carambia","year":"2013","unstructured":"Carambia A, Frenzel C, Bruns OT, Schwinge D, Reimer R, Hohenberg H, et al. Inhibition of inflammatory CD4 t cell activity by murine liver sinusoidal endothelial cells. J Hepatol. 2013;58(1):112\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2012.09.008.","journal-title":"J Hepatol"},{"issue":"1","key":"1982_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.21965","volume":"47","author":"L Diehl","year":"2008","unstructured":"Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA. Tolerogenic maturation of liver sinusoidal endothelial cells promotes b7-homolog 1-dependent CD8\u2009+\u2009t cell tolerance. Hepatology. 2008;47(1):296\u2013305. https:\/\/doi.org\/10.1002\/hep.21965.","journal-title":"Hepatology"},{"issue":"1","key":"1982_CR4","doi-asserted-by":"publisher","first-page":"16123","DOI":"10.1038\/s41598-018-34522-4","volume":"8","author":"F Tolksdorf","year":"2018","unstructured":"Tolksdorf F, Mikulec J, Geers B, Endig J, Sprezyna P, Heukamp LC, et al. The PDL1-inducible GTPase arl4d controls t effector function by limiting IL-2 production. Sci Rep. 2018;8(1):16123. https:\/\/doi.org\/10.1038\/s41598-018-34522-4.","journal-title":"Sci Rep"},{"key":"1982_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.intimp.2017.04.009","volume":"48","author":"J Gong","year":"2017","unstructured":"Gong J, Cao D, Chen Y, Li J, Gong J, Zeng Z. Role of programmed death ligand 1 and Kupffer cell in immune regulation after orthotopic liver transplantation in rats. Int Immunopharmacol. 2017;48:8\u201316. https:\/\/doi.org\/10.1016\/j.intimp.2017.04.009.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1982_CR6","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/hep.23843","volume":"52","author":"H Ji","year":"2010","unstructured":"Ji H, Shen X, Gao F, Ke B, Freitas MC, Uchida Y, et al. Programmed death-1\/b7-h1 negative costimulation protects mouse liver against ischemia and reperfusion injury. Hepatology. 2010;52(4):1380\u20139. https:\/\/doi.org\/10.1002\/hep.23843.","journal-title":"Hepatology"},{"issue":"2","key":"1982_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1152\/physrev.00004.2023","volume":"105","author":"V Ronca","year":"2025","unstructured":"Ronca V, Gerussi A, Collins P, Parente A, Oo YH, Invernizzi P. The liver as a central hub of the immune system: pathophysiological implications. Physiol Rev. 2025;105(2):493\u2013539. https:\/\/doi.org\/10.1152\/physrev.00004.2023.","journal-title":"Physiol Rev"},{"issue":"10","key":"1982_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41577-023-00867-9","volume":"23","author":"K Chamoto","year":"2023","unstructured":"Chamoto K, Yaguchi T, Tajima M, Honjo T. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immunol. 2023;23(10):682\u201395. https:\/\/doi.org\/10.1038\/s41577-023-00867-9.","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"1982_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378. https:\/\/doi.org\/10.1056\/NEJMra1514296.","journal-title":"N Engl J Med"},{"issue":"4","key":"1982_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A Cheng","year":"2022","unstructured":"Cheng A, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030.","journal-title":"J Hepatol"},{"issue":"1","key":"1982_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4143\/crt.2016.066","volume":"49","author":"HI Jung","year":"2017","unstructured":"Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, et al. Overexpression of PD-l1 and PD-l2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017;49(1):246\u201354. https:\/\/doi.org\/10.4143\/crt.2016.066.","journal-title":"Cancer Res Treat"},{"issue":"9","key":"1982_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/liv.15666","volume":"43","author":"T Zeng","year":"2023","unstructured":"Zeng T, Zhao Q, Liu J, Dai B, Wang T, Yang F, et al. Expression pattern of PD-1\/PD-l1 in primary liver cancer with clinical correlation. Liver Int. 2023;43(9):1995\u20132001. https:\/\/doi.org\/10.1111\/liv.15666.","journal-title":"Liver Int"},{"key":"1982_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3389\/fonc.2019.00883","volume":"9","author":"H Liao","year":"2019","unstructured":"Liao H, Chen W, Dai Y, Richardson JJ, Guo J, Yuan K, et al. Expression of programmed cell death-ligands in hepatocellular carcinoma: correlation with immune microenvironment and survival outcomes. Front Oncol. 2019;9:883. https:\/\/doi.org\/10.3389\/fonc.2019.00883.","journal-title":"Front Oncol"},{"issue":"2","key":"1982_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2022.02.032","volume":"77","author":"M Barsch","year":"2022","unstructured":"Barsch M, Sali\u00e9 H, Schlaak AE, Zhang Z, Hess M, Mayer LS, et al. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. J Hepatol. 2022;77(2):397\u2013409. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.032.","journal-title":"J Hepatol"},{"issue":"8","key":"1982_CR15","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","volume":"54","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Gunasegaran B, Singh HD, Dutertre CA, Loh CY, Lim JQ, et al. Non-terminally exhausted tumor-resident memory HBV-specific t cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity. 2021;54(8):1825\u201340. https:\/\/doi.org\/10.1016\/j.immuni.2021.06.013.","journal-title":"Immunity"},{"issue":"1","key":"1982_CR16","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1038\/s41467-023-43381-1","volume":"14","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns S, Philips G, Vandecaveye V, Boeckx B, Schepers R, Van Brussel T, et al. PD-1(-) CD45RA(+) effector-memory CD8 t cells and CXCL10(+) macrophages are associated with response to Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat Commun. 2023;14(1):7825. https:\/\/doi.org\/10.1038\/s41467-023-43381-1.","journal-title":"Nat Commun"},{"issue":"6","key":"1982_CR17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell-CD4(+) t helper cell niches enable CD8(+) t cell differentiation following PD-1 Blockade in hepatocellular carcinoma. Nat Med. 2023;29(6):1389\u201399. https:\/\/doi.org\/10.1038\/s41591-023-02345-0.","journal-title":"Nat Med"},{"key":"1982_CR18","doi-asserted-by":"publisher","first-page":"111601","DOI":"10.1016\/j.intimp.2024.111601","volume":"129","author":"M Song","year":"2024","unstructured":"Song M, Wang L, Jiang S, Liang J, Li W, Rao W, et al. Pathogenic th17 cell-mediated liver fibrosis contributes to resistance to PD-l1 antibody immunotherapy in hepatocellular carcinoma. Int Immunopharmacol. 2024;129:111601. https:\/\/doi.org\/10.1016\/j.intimp.2024.111601.","journal-title":"Int Immunopharmacol"},{"issue":"17","key":"1982_CR19","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","volume":"186","author":"B Ruf","year":"2023","unstructured":"Ruf B, Bruhns M, Babaei S, Kedei N, Ma L, Revsine M, et al. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. Cell. 2023;186(17):3686\u2013705. https:\/\/doi.org\/10.1016\/j.cell.2023.07.026.","journal-title":"Cell"},{"key":"1982_CR20","doi-asserted-by":"publisher","unstructured":"Huang W, Ye D, He W, He X, Shi X, Gao Y. Activated but impaired IFN-\u03b3 production of mucosal-associated invariant t cells in patients with hepatocellular carcinoma. J Immunother Cancer. 2021;9(11). https:\/\/doi.org\/10.1136\/jitc-2021-003685.","DOI":"10.1136\/jitc-2021-003685"},{"issue":"11","key":"1982_CR21","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1158\/1078-0432.CCR-18-3040","volume":"25","author":"M Duan","year":"2019","unstructured":"Duan M, Goswami S, Shi JY, Wu LJ, Wang XY, Ma JQ, et al. Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin Cancer Res. 2019;25(11):3304\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3040.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1982_CR22","doi-asserted-by":"publisher","first-page":"2002068","DOI":"10.1080\/2162402X.2021.2002068","volume":"10","author":"L Tao","year":"2021","unstructured":"Tao L, Wang S, Kang G, Jiang S, Yin W, Zong L, et al. PD-1 Blockade improves the anti-tumor potency of exhausted CD3(+)CD56(+) NKT-like cells in patients with primary hepatocellular carcinoma. Oncoimmunology. 2021;10(1):2002068. https:\/\/doi.org\/10.1080\/2162402X.2021.2002068.","journal-title":"Oncoimmunology"},{"key":"1982_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2023.01.006","volume":"644","author":"R Yang","year":"2023","unstructured":"Yang R, He Q, Zhang J, Yan Y, Shi J, Zhou P. The redirected killing of PD-l1 positive tumor cells by the expanded mucosa-associated invariant t (MAIT) cells is mediated with a bispecific antibody targeting TCR v\u03b17.2 and PD-l1. Biochem Biophys Res Commun. 2023;644:1\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2023.01.006.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1982_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.13624","volume":"169","author":"L Chen","year":"2023","unstructured":"Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, et al. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting glypican-3 in hepatocellular carcinoma. Immunology. 2023;169(2):204\u201318. https:\/\/doi.org\/10.1111\/imm.13624.","journal-title":"Immunology"},{"issue":"6","key":"1982_CR25","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/hep.32062","volume":"74","author":"Q He","year":"2021","unstructured":"He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, et al. IL-1\u03b2-induced elevation of solute carrier family 7 member 11 promotes hepatocellular carcinoma metastasis through up-regulating programmed death ligand 1 and colony-stimulating factor 1. Hepatology. 2021;74(6):3174\u201393. https:\/\/doi.org\/10.1002\/hep.32062.","journal-title":"Hepatology"},{"issue":"1","key":"1982_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40164-023-00378-2","volume":"12","author":"ZQ Chen","year":"2023","unstructured":"Chen ZQ, Zuo XL, Cai J, Zhang Y, Han GY, Zhang L, et al. Hypoxia-associated circPRDM4 promotes immune escape via HIF-1\u03b1 regulation of PD-l1 in hepatocellular carcinoma. Exp Hematol Oncol. 2023;12(1):17. https:\/\/doi.org\/10.1186\/s40164-023-00378-2.","journal-title":"Exp Hematol Oncol"},{"key":"1982_CR27","doi-asserted-by":"publisher","first-page":"112415","DOI":"10.1016\/j.intimp.2024.112415","volume":"136","author":"J Qiu","year":"2024","unstructured":"Qiu J, Zhong F, Zhang Z, Pan B, Ye D, Zhang X, et al. Hypoxia-responsive LncRNA MIR155HG promotes PD-l1 expression in hepatocellular carcinoma cells by enhancing HIF-1\u03b1 mRNA stability. Int Immunopharmacol. 2024;136:112415. https:\/\/doi.org\/10.1016\/j.intimp.2024.112415.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"1982_CR28","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1007\/s00262-023-03563-8","volume":"72","author":"B Yao","year":"2023","unstructured":"Yao B, Lu Y, Li Y, Bai Y, Wei X, Yang Y, et al. BCLAF1-induced HIF-1\u03b1 accumulation under normoxia enhances PD-l1 treatment resistances via BCLAF1-CUL3 complex. Cancer Immunol Immunother. 2023;72(12):4279\u201392. https:\/\/doi.org\/10.1007\/s00262-023-03563-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"39","key":"1982_CR29","doi-asserted-by":"publisher","first-page":"e2402115","DOI":"10.1002\/advs.202402115","volume":"11","author":"H Liu","year":"2024","unstructured":"Liu H, Li X, Zhang C, Hao X, Cao Y, Wang Y, et al. GJB2 promotes HCC progression by activating Glycolysis through cytoplasmic translocation and generating a suppressive tumor microenvironment based on single cell RNA sequencing. Adv Sci (Weinh). 2024;11(39):e2402115. https:\/\/doi.org\/10.1002\/advs.202402115.","journal-title":"Adv Sci (Weinh)"},{"key":"1982_CR30","doi-asserted-by":"publisher","first-page":"111376","DOI":"10.1016\/j.intimp.2023.111376","volume":"127","author":"X Luo","year":"2024","unstructured":"Luo X, Zhang Z, Li S, Wang Y, Sun M, Hu D, et al. SRSF10 facilitates HCC growth and metastasis by suppressing CD8(+)t cell infiltration and targeting SRSF10 enhances anti-PD-l1 therapy. Int Immunopharmacol. 2024;127:111376. https:\/\/doi.org\/10.1016\/j.intimp.2023.111376.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"1982_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/imm.13853","volume":"173","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wu T, Wang Y, Luo D, Zhao Z, Sun H, et al. Hypoxic tumour-derived Exosomal mir-1290 exacerbates the suppression of CD8\u2009+\u2009t cells by promoting m2 macrophage polarization. Immunology. 2024;173(4):672\u201388. https:\/\/doi.org\/10.1111\/imm.13853.","journal-title":"Immunology"},{"issue":"10","key":"1982_CR32","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1136\/gutjnl-2022-327924","volume":"72","author":"Y Fu","year":"2023","unstructured":"Fu Y, Mackowiak B, Feng D, Lu H, Guan Y, Lehner T, et al. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression. Gut. 2023;72(10):1942\u201358. https:\/\/doi.org\/10.1136\/gutjnl-2022-327924.","journal-title":"Gut"},{"issue":"10","key":"1982_CR33","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41556-020-0575-z","volume":"22","author":"J Hou","year":"2020","unstructured":"Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, et al. PD-l1-mediated gasdermin c expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264\u201375. https:\/\/doi.org\/10.1038\/s41556-020-0575-z.","journal-title":"Nat Cell Biol"},{"key":"1982_CR34","doi-asserted-by":"publisher","first-page":"156555","DOI":"10.1016\/j.cyto.2024.156555","volume":"177","author":"YT Ma","year":"2024","unstructured":"Ma YT, Zheng L, Zhao CW, Zhang Y, Xu XW, Wang XY, et al. Interferon-\u03b1 induces differentiation of cancer stem cells and immunosuppression in hepatocellular carcinoma by upregulating CXCL8 secretion. Cytokine. 2024;177:156555. https:\/\/doi.org\/10.1016\/j.cyto.2024.156555.","journal-title":"Cytokine"},{"issue":"9","key":"1982_CR35","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00262-020-02586-9","volume":"69","author":"Y Yan","year":"2020","unstructured":"Yan Y, Zheng L, Du Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-l1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;69(9):1891\u2013903. https:\/\/doi.org\/10.1007\/s00262-020-02586-9.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1982_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1053\/j.gastro.2019.10.025","volume":"158","author":"J Xiang","year":"2020","unstructured":"Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, et al. Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via MEF2d regulation of programmed cell death 1 ligand 1 in hepatocellular carcinoma cells. Gastroenterology. 2020;158(3):664\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2019.10.025.","journal-title":"Gastroenterology"},{"key":"1982_CR37","doi-asserted-by":"publisher","first-page":"114318","DOI":"10.1016\/j.colsurfb.2024.114318","volume":"245","author":"J Du","year":"2025","unstructured":"Du J, Que Z, Aihaiti A, Zhai M, Zhang Z, Shao Y, et al. Co-delivery of SN38 and MEF2d-siRNA via tlyp-1-modified liposomes reverses PD-l1 expression induced by STING activation in hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2025;245:114318. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.114318.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"1982_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/cas.16076","volume":"115","author":"J Liu","year":"2024","unstructured":"Liu J, Yang T, Luo Y, Ma Z, Yu Z, Zhang L, et al. DEAD-box helicase 1 inhibited CD8(+) t cell antitumor activity by inducing PD-l1 expression in hepatocellular carcinoma. Cancer Sci. 2024;115(3):763\u201376. https:\/\/doi.org\/10.1111\/cas.16076.","journal-title":"Cancer Sci"},{"key":"1982_CR39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.freeradbiomed.2023.12.034","volume":"212","author":"T Li","year":"2024","unstructured":"Li T, Huang HY, Qian B, Wang WH, Yuan Q, Zhang HY, et al. Interventing mitochondrial PD-l1 suppressed IFN-\u03b3-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis. Free Radic Biol Med. 2024;212:360\u201374. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2023.12.034.","journal-title":"Free Radic Biol Med"},{"issue":"11","key":"1982_CR40","first-page":"3705","volume":"10","author":"J Yan","year":"2020","unstructured":"Yan J, Zhou B, Guo L, Chen Z, Zhang B, Liu S, et al. GOLM1 upregulates expression of PD-l1 through EGFR\/STAT3 pathway in hepatocellular carcinoma. Am J Cancer Res. 2020;10(11):3705\u201320.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"1982_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cac2.12117","volume":"41","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ning F, Cai Y, Sheng H, Zheng R, Yin X, et al. The EGFR-p38 MAPK axis up-regulates PD-l1 through mir-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells. Cancer Commun (Lond). 2021;41(1):62\u201378. https:\/\/doi.org\/10.1002\/cac2.12117.","journal-title":"Cancer Commun (Lond)"},{"key":"1982_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jare.2024.08.021","volume":"73","author":"S Wang","year":"2025","unstructured":"Wang S, Yuan X, Yang Z, Zhang X, Xu Z, Yang L, et al. Matrix stiffness-dependent PD-l2 deficiency improves SMYD3\/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC. J Adv Res. 2025;73:265\u201382. https:\/\/doi.org\/10.1016\/j.jare.2024.08.021.","journal-title":"J Adv Res"},{"issue":"1","key":"1982_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41419-025-07482-7","volume":"16","author":"C Ding","year":"2025","unstructured":"Ding C, Yan F, Xu B, Qian H, Hong X, Liu S, et al. PRMT3 drives PD-l1-mediated immune escape through activating PDHK1-regulated Glycolysis in hepatocellular carcinoma. Cell Death Dis. 2025;16(1):158. https:\/\/doi.org\/10.1038\/s41419-025-07482-7.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1982_CR44","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ptr.7695","volume":"37","author":"Q Peng","year":"2023","unstructured":"Peng Q, Li S, Shi X, Guo Y, Hao L, Zhang Z, et al. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy. Phytother Res. 2023;37(5):1740\u201353. https:\/\/doi.org\/10.1002\/ptr.7695.","journal-title":"Phytother Res"},{"issue":"6","key":"1982_CR45","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-l1 and PD-l2 expression. Cell Rep. 2017;19(6):1189\u2013201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031.","journal-title":"Cell Rep"},{"issue":"41","key":"1982_CR46","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1038\/s41388-024-03140-y","volume":"43","author":"H Han","year":"2024","unstructured":"Han H, Shi Q, Zhang Y, Ding M, He X, Liu C, et al. RBM12 drives PD-l1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation. Oncogene. 2024;43(41):3062\u201377. https:\/\/doi.org\/10.1038\/s41388-024-03140-y.","journal-title":"Oncogene"},{"issue":"1","key":"1982_CR47","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s41467-024-45712-2","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang M, Ye L, Shen S, Zhang Y, Qian X, et al. HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-l1 expression. Nat Commun. 2024;15(1):1314. https:\/\/doi.org\/10.1038\/s41467-024-45712-2.","journal-title":"Nat Commun"},{"issue":"1","key":"1982_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.31083\/j.fbl2901039","volume":"29","author":"S Guo","year":"2024","unstructured":"Guo S, Yang Q. Bioinformatics analysis identifies PLA2g7 as a key antigen-presenting prognostic related gene promoting hepatocellular carcinoma through the STAT1\/PD-l1 axis. Front Biosci (Landmark Ed). 2024;29(1):39. https:\/\/doi.org\/10.31083\/j.fbl2901039.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1982_CR49","doi-asserted-by":"publisher","unstructured":"Lv T, Xiong X, Yan W, Liu M, Xu H, He Q. Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-l1 expression. J Immunother Cancer. 2022;10(6). https:\/\/doi.org\/10.1136\/jitc-2022-004763.","DOI":"10.1136\/jitc-2022-004763"},{"issue":"1","key":"1982_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","volume":"33","author":"H Lv","year":"2021","unstructured":"Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, et al. NAD(+) metabolism maintains inducible PD-l1 expression to drive tumor immune evasion. Cell Metab. 2021;33(1):110\u201327. https:\/\/doi.org\/10.1016\/j.cmet.2020.10.021.","journal-title":"Cell Metab"},{"key":"1982_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.02.034","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wang J, Chen Y, Lin W, Zhou R, Zhao L, et al. NRIR promotes immune escape in hepatocellular cancer by regulating IFN\u03b3-induced PD-l1 expression. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.02.034.","journal-title":"J Adv Res"},{"issue":"1","key":"1982_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19(1):145. https:\/\/doi.org\/10.1186\/s12943-020-01258-7.","journal-title":"Mol Cancer"},{"issue":"7","key":"1982_CR53","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","volume":"181","author":"AV Villarino","year":"2020","unstructured":"Villarino AV, Gadina M, O\u2019Shea JJ, Kanno Y. SnapShot: jak-STAT signaling II. Cell. 2020;181(7):1696. https:\/\/doi.org\/10.1016\/j.cell.2020.04.052.","journal-title":"Cell"},{"issue":"14","key":"1982_CR54","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.7150\/thno.44417","volume":"10","author":"B Zhou","year":"2020","unstructured":"Zhou B, Yan J, Guo L, Zhang B, Liu S, Yu M, et al. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-l1 upregulation in hepatocellular carcinoma. Theranostics. 2020;10(14):6530\u201343. https:\/\/doi.org\/10.7150\/thno.44417.","journal-title":"Theranostics"},{"issue":"4","key":"1982_CR55","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41417-025-00890-z","volume":"32","author":"Z Xie","year":"2025","unstructured":"Xie Z, Wu Y, Peng N, Wang J, Wang H, Zhao L. BAIAP2l2 facilitates hepatocellular carcinoma progression and immune evasion of via targeting JAK1-mediated pathway and PD-l1 expression. Cancer Gene Ther. 2025;32(4):464\u201374. https:\/\/doi.org\/10.1038\/s41417-025-00890-z.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1982_CR56","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41416-021-01337-6","volume":"125","author":"Y Yan","year":"2021","unstructured":"Yan Y, Zheng L, Du Q, Cui X, Dong K, Guo Y, et al. Interferon regulatory factor 1 (IRF-1) downregulates checkpoint kinase 1 (CHK1) through mir-195 to upregulate apoptosis and PD-l1 expression in hepatocellular carcinoma (HCC) cells. Br J Cancer. 2021;125(1):101\u201311. https:\/\/doi.org\/10.1038\/s41416-021-01337-6.","journal-title":"Br J Cancer"},{"key":"1982_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejpb.2022.10.017","volume":"181","author":"Y Ma","year":"2022","unstructured":"Ma Y, Li J, Zhao Y, Hu B, Liu Y, Liu C. Nanobubble-mediated co-delivery of ce6 and mir-195 for synergized sonodynamic and checkpoint Blockade combination therapy with elicitation of robust immune response in hepatocellular carcinoma. Eur J Pharm Biopharm. 2022;181:36\u201348. https:\/\/doi.org\/10.1016\/j.ejpb.2022.10.017.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1982_CR58","doi-asserted-by":"publisher","first-page":"16998","DOI":"10.1038\/s41598-023-42948-8","volume":"13","author":"R Wu","year":"2023","unstructured":"Wu R, Liu W, Yang Q, Zhang J, Hou P, Xiong J, et al. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-l1 expression. Sci Rep. 2023;13(1):16998. https:\/\/doi.org\/10.1038\/s41598-023-42948-8.","journal-title":"Sci Rep"},{"issue":"1","key":"1982_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2022.2156242","volume":"24","author":"H Cheng","year":"2023","unstructured":"Cheng H, Wang S, Huang A, Ma J, Gao D, Li M, et al. HSF1 is involved in immunotherapeutic response through regulating APOJ\/STAT3-mediated PD-l1 expression in hepatocellular carcinoma. Cancer Biol Ther. 2023;24(1):1\u20139. https:\/\/doi.org\/10.1080\/15384047.2022.2156242.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1982_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13046-023-02609-0","volume":"42","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xu Q, Deng F, Zheng Z, Luo J, Wang P, et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res. 2023;42(1):38. https:\/\/doi.org\/10.1186\/s13046-023-02609-0.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"1982_CR61","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41419-024-06897-y","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Sandrine IK, Ma L, Chen K, Chen X, Yu Y, et al. TNKS1BP1 facilitates ubiquitination of CNOT4 by TRIM21 to promote hepatocellular carcinoma progression and immune evasion. Cell Death Dis. 2024;15(7):511. https:\/\/doi.org\/10.1038\/s41419-024-06897-y.","journal-title":"Cell Death Dis"},{"key":"1982_CR62","doi-asserted-by":"publisher","unstructured":"Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. \u0392-catenin signaling in hepatocellular carcinoma. J Clin Invest. 2022;132(4). https:\/\/doi.org\/10.1172\/JCI154515.","DOI":"10.1172\/JCI154515"},{"key":"1982_CR63","doi-asserted-by":"publisher","first-page":"111039","DOI":"10.1016\/j.cellsig.2024.111039","volume":"115","author":"B Pan","year":"2024","unstructured":"Pan B, Ke X, Qiu J, Ye D, Zhang Z, Zhang X, et al. LAIR1-mediated resistance of hepatocellular carcinoma cells to t cells through a GSK-3\u03b2\/\u03b2-catenin\/MYC\/PD-l1 pathway. Cell Signal. 2024;115:111039. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111039.","journal-title":"Cell Signal"},{"issue":"1","key":"1982_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10020-025-01088-7","volume":"31","author":"CY Yao","year":"2025","unstructured":"Yao CY, Tao HT, He JJ, Zhu FY, Xie CQ, Cheng YN, et al. NUAK1 acts as a novel regulator of PD-l1 via activating GSK-3\u03b2\/\u03b2-catenin pathway in hepatocellular carcinoma. Mol Med. 2025;31(1):38. https:\/\/doi.org\/10.1186\/s10020-025-01088-7.","journal-title":"Mol Med"},{"issue":"5","key":"1982_CR65","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s13402-023-00811-y","volume":"46","author":"W Xie","year":"2023","unstructured":"Xie W, Shi L, Quan H, Xiao H, Chen J, Liu J, et al. SYVN1 ubiquitinates FoxO1 to induce \u03b2-catenin nuclear translocation, PD-l1-mediated metastasis, and immune evasion of hepatocellular carcinoma. Cell Oncol (Dordr). 2023;46(5):1285\u201399. https:\/\/doi.org\/10.1007\/s13402-023-00811-y.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"1982_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, et al. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-l1 and CCL2. J Hepatol. 2023;79(1):109\u201325. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.036.","journal-title":"J Hepatol"},{"key":"1982_CR67","doi-asserted-by":"publisher","first-page":"115955","DOI":"10.1016\/j.biopha.2023.115955","volume":"170","author":"C Guo","year":"2024","unstructured":"Guo C, Zhou N, Lu Y, Mu M, Li Z, Zhang X, et al. FGF19\/FGFR4 signaling contributes to hepatocellular carcinoma survival and immune escape by regulating IGF2BP1-mediated expression of PD-l1. Biomed Pharmacother. 2024;170:115955. https:\/\/doi.org\/10.1016\/j.biopha.2023.115955.","journal-title":"Biomed Pharmacother"},{"key":"1982_CR68","doi-asserted-by":"publisher","first-page":"115378","DOI":"10.1016\/j.bcp.2022.115378","volume":"208","author":"RH Yang","year":"2023","unstructured":"Yang RH, Qin J, Cao JL, Zhang MZ, Li YY, Wang MQ, et al. Dickkopf-1 drives tumor immune evasion by inducing PD-l1 expression in hepatocellular carcinoma. Biochem Pharmacol. 2023;208:115378. https:\/\/doi.org\/10.1016\/j.bcp.2022.115378.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"1982_CR69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3350\/cmh.2024.0934","volume":"31","author":"W Zeng","year":"2025","unstructured":"Zeng W, Liu F, Liu Y, Zhang Z, Hu H, Ning S, et al. Targeting TM4SF1 promotes tumor senescence enhancing CD8\u2009+\u2009t cell cytotoxic function in hepatocellular carcinoma. Clin Mol Hepatol. 2025;31(2):489\u2013508. https:\/\/doi.org\/10.3350\/cmh.2024.0934.","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"1982_CR70","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","volume":"156","author":"H Li","year":"2019","unstructured":"Li H, Li C, Li X, Ding Q, Guo L, Liu S, et al. MET inhibitors promote liver tumor evasion of the immune response by stabilizing PDL1. Gastroenterology. 2019;156(6):1849\u201361. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.252.","journal-title":"Gastroenterology"},{"issue":"11","key":"1982_CR71","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41423-020-00549-9","volume":"17","author":"R Deng","year":"2020","unstructured":"Deng R, Zuo C, Li Y, Xue B, Xun Z, Guo Y, et al. The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical wnt\/\u03b2-catenin signaling pathway. Cell Mol Immunol. 2020;17(11):1163\u201379. https:\/\/doi.org\/10.1038\/s41423-020-00549-9.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1982_CR72","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41467-021-23864-9","volume":"12","author":"M Wu","year":"2021","unstructured":"Wu M, Xia X, Hu J, Fowlkes NW, Li S. WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-l1 expression. Nat Commun. 2021;12(1):3500. https:\/\/doi.org\/10.1038\/s41467-021-23864-9.","journal-title":"Nat Commun"},{"issue":"29","key":"1982_CR73","doi-asserted-by":"publisher","first-page":"e2301928","DOI":"10.1002\/advs.202301928","volume":"10","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang Y, Lu Z, Wan J, Jiang L, Song D, et al. PGAM1 Inhibition promotes HCC ferroptosis and synergizes with anti-PD-1 immunotherapy. Adv Sci (Weinh). 2023;10(29):e2301928. https:\/\/doi.org\/10.1002\/advs.202301928.","journal-title":"Adv Sci (Weinh)"},{"issue":"6","key":"1982_CR74","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/cas.15753","volume":"114","author":"X Kong","year":"2023","unstructured":"Kong X, Peng H, Liu P, Fu X, Wang N, Zhang D. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2\/\u03b2-catenin signaling pathway. Cancer Sci. 2023;114(6):2265\u201376. https:\/\/doi.org\/10.1111\/cas.15753.","journal-title":"Cancer Sci"},{"key":"1982_CR75","doi-asserted-by":"publisher","unstructured":"Yu J, Ling S, Hong J, Zhang L, Zhou W, Yin L, et al. TP53\/mTORC1-mediated bidirectional regulation of PD-l1 modulates immune evasion in hepatocellular carcinoma. J Immunother Cancer. 2023;11(11). https:\/\/doi.org\/10.1136\/jitc-2023-007479.","DOI":"10.1136\/jitc-2023-007479"},{"issue":"10","key":"1982_CR76","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/s12276-023-01060-7","volume":"55","author":"J Zhang","year":"2023","unstructured":"Zhang J, Lin XT, Yu HQ, Fang L, Wu D, Luo YD, et al. Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice. Exp Mol Med. 2023;55(10):2162\u201376. https:\/\/doi.org\/10.1038\/s12276-023-01060-7.","journal-title":"Exp Mol Med"},{"issue":"9\u201310","key":"1982_CR77","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s10495-024-01982-1","volume":"29","author":"Q Wang","year":"2024","unstructured":"Wang Q, Tan W, Zhang Z, Chen Q, Xie Z, Yang L, et al. FAT10 induces immune suppression by upregulating PD-l1 expression in hepatocellular carcinoma. Apoptosis. 2024;29(9\u201310):1529\u201345. https:\/\/doi.org\/10.1007\/s10495-024-01982-1.","journal-title":"Apoptosis"},{"key":"1982_CR78","doi-asserted-by":"publisher","first-page":"1480834","DOI":"10.3389\/fimmu.2024.1480834","volume":"15","author":"X Ye","year":"2024","unstructured":"Ye X, Lin J, Chen Y, Wang X. IGF2BP1 accelerates the aerobic Glycolysis to boost its immune escape in hepatocellular carcinoma microenvironment. Front Immunol. 2024;15:1480834. https:\/\/doi.org\/10.3389\/fimmu.2024.1480834.","journal-title":"Front Immunol"},{"issue":"4","key":"1982_CR79","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00109-022-02179-2","volume":"100","author":"R Xu","year":"2022","unstructured":"Xu R, Liu X, Li A, Song L, Liang J, Gao J, et al. C-met up-regulates the expression of PD-l1 through MAPK\/NF-\u03babp65 pathway. J Mol Med (Berl). 2022;100(4):585\u201398. https:\/\/doi.org\/10.1007\/s00109-022-02179-2.","journal-title":"J Mol Med (Berl)"},{"key":"1982_CR80","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.025","author":"J Chen","year":"2024","unstructured":"Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, et al. TGF-\u03b21-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-l1 and CXCL12. Gastroenterology. 2024. https:\/\/doi.org\/10.1053\/j.gastro.2024.02.025.","journal-title":"Gastroenterology"},{"issue":"3","key":"1982_CR81","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jcmgh.2022.12.002","volume":"15","author":"F Zhang","year":"2023","unstructured":"Zhang F, Hu K, Liu W, Quan B, Li M, Lu S, et al. Oxaliplatin-resistant hepatocellular carcinoma drives immune evasion through PD-l1 up-regulation and PMN-singular recruitment. Cell Mol Gastroenterol Hepatol. 2023;15(3):573\u201391. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.12.002.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"1982_CR82","doi-asserted-by":"publisher","first-page":"7677","DOI":"10.1038\/s41467-022-35469-x","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Zhang L, You W, Xu J, Dai J, Hua D, et al. PRDM1\/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-l1 axis in hepatocellular carcinoma cells. Nat Commun. 2022;13(1):7677. https:\/\/doi.org\/10.1038\/s41467-022-35469-x.","journal-title":"Nat Commun"},{"issue":"1","key":"1982_CR83","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41420-025-02540-7","volume":"11","author":"Y Li","year":"2025","unstructured":"Li Y, Zhu J, Zhai F, Ge Y, Zhan Z, Wang S, et al. LMNB2-mediated high PD-l1 transcription triggers the immune escape of hepatocellular carcinoma. Cell Death Discov. 2025;11(1):269. https:\/\/doi.org\/10.1038\/s41420-025-02540-7.","journal-title":"Cell Death Discov"},{"issue":"15","key":"1982_CR84","doi-asserted-by":"publisher","first-page":"e2206669","DOI":"10.1002\/advs.202206669","volume":"10","author":"D Zhang","year":"2023","unstructured":"Zhang D, Man D, Lu J, Jiang Y, Ding B, Su R, et al. Mitochondrial TSPO promotes hepatocellular carcinoma progression through ferroptosis Inhibition and immune evasion. Adv Sci (Weinh). 2023;10(15):e2206669. https:\/\/doi.org\/10.1002\/advs.202206669.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"1982_CR85","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ymthe.2023.01.002","volume":"31","author":"T Patra","year":"2023","unstructured":"Patra T, Cunningham DM, Meyer K, Toth K, Ray RB, Heczey A, et al. Targeting lin28 axis enhances glypican-3-CAR t cell efficacy against hepatic tumor initiating cell population. Mol Ther. 2023;31(3):715\u201328. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.002.","journal-title":"Mol Ther"},{"key":"1982_CR86","doi-asserted-by":"publisher","first-page":"577108","DOI":"10.3389\/fphar.2020.577108","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang X, Liang C, Yao X, Yang RH, Zhang ZS, Liu FY, et al. PKM2-induced the phosphorylation of histone h3 contributes to EGF-mediated PD-l1 transcription in HCC. Front Pharmacol. 2020;11:577108. https:\/\/doi.org\/10.3389\/fphar.2020.577108.","journal-title":"Front Pharmacol"},{"key":"1982_CR87","doi-asserted-by":"publisher","first-page":"9965099","DOI":"10.1155\/2021\/9965099","volume":"2021","author":"Y Wang","year":"2021","unstructured":"Wang Y, Cao K. KDM1a promotes immunosuppression in hepatocellular carcinoma by regulating PD-l1 through demethylating MEF2d. J Immunol Res. 2021;2021:9965099. https:\/\/doi.org\/10.1155\/2021\/9965099.","journal-title":"J Immunol Res"},{"issue":"1","key":"1982_CR88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41420-025-02462-4","volume":"11","author":"H Quan","year":"2025","unstructured":"Quan H, Zhou H, Chen F, Chen J, He Y, Xiao H, et al. Acetylated KIAA1429 by TIP60 facilitates metastasis and immune evasion of hepatocellular carcinoma via n6-methyladenosine-KDM5b-mediated regulation of FoxO1. Cell Death Discov. 2025;11(1):210. https:\/\/doi.org\/10.1038\/s41420-025-02462-4.","journal-title":"Cell Death Discov"},{"issue":"3","key":"1982_CR89","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/iep.12440","volume":"103","author":"X Zhang","year":"2022","unstructured":"Zhang X, Pan B, Qiu J, Ke X, Shen S, Wang X, et al. LncRNA MIAT targets mir-411-5p\/STAT3\/PD-l1 axis mediating hepatocellular carcinoma immune response. Int J Exp Pathol. 2022;103(3):102\u201311. https:\/\/doi.org\/10.1111\/iep.12440.","journal-title":"Int J Exp Pathol"},{"key":"1982_CR90","doi-asserted-by":"publisher","first-page":"9289719","DOI":"10.1155\/2021\/9289719","volume":"2021","author":"C Zeng","year":"2021","unstructured":"Zeng C, Ye S, Chen Y, Zhang Q, Luo Y, Gai L, et al. HOXA-as3 promotes proliferation and migration of hepatocellular carcinoma cells via the mir-455-5p\/PD-l1 axis. J Immunol Res. 2021;2021:9289719. https:\/\/doi.org\/10.1155\/2021\/9289719.","journal-title":"J Immunol Res"},{"issue":"9","key":"1982_CR91","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/cbin.12049","volume":"47","author":"T He","year":"2023","unstructured":"He T, Huang J, Liang H, Zhong B, Xu G, Zhu X. Circular RNA hsa_circ_0005239 contributes to hepatocellular carcinoma cell migration, invasion, and angiogenesis by targeting the mir-34a-5p\/PD-l1 axis. Cell Biol Int. 2023;47(9):1519\u201334. https:\/\/doi.org\/10.1002\/cbin.12049.","journal-title":"Cell Biol Int"},{"issue":"1","key":"1982_CR92","doi-asserted-by":"publisher","first-page":"102125","DOI":"10.1016\/j.omtn.2024.102125","volume":"35","author":"B Zhao","year":"2024","unstructured":"Zhao B, Zheng X, Wang Y, Cheng N, Zhong Y, Zhou Y, et al. Lnc-CCNH-8 promotes immune escape by up-regulating PD-l1 in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2024;35(1):102125. https:\/\/doi.org\/10.1016\/j.omtn.2024.102125.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1982_CR93","doi-asserted-by":"publisher","first-page":"876048","DOI":"10.3389\/fimmu.2022.876048","volume":"13","author":"X Kong","year":"2022","unstructured":"Kong X, Zheng Z, Song G, Zhang Z, Liu H, Kang J, et al. Over-expression of GUSB leads to primary resistance of anti-PD1 therapy in hepatocellular carcinoma. Front Immunol. 2022;13:876048. https:\/\/doi.org\/10.3389\/fimmu.2022.876048.","journal-title":"Front Immunol"},{"key":"1982_CR94","doi-asserted-by":"publisher","first-page":"217470","DOI":"10.1016\/j.canlet.2025.217470","volume":"612","author":"L Yang","year":"2025","unstructured":"Yang L, Tan W, Wang M, Wei Y, Xie Z, Wang Q, et al. CircCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation. Cancer Lett. 2025;612:217470. https:\/\/doi.org\/10.1016\/j.canlet.2025.217470.","journal-title":"Cancer Lett"},{"issue":"4","key":"1982_CR95","doi-asserted-by":"publisher","first-page":"267","DOI":"10.5582\/bst.2022.01281","volume":"16","author":"L Liu","year":"2022","unstructured":"Liu L, Liao R, Wu Z, Du C, You Y, Que K, et al. Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma via the miRNA-4474-3p-ALOX-15 and EMT axes. Biosci Trends. 2022;16(4):267\u201381. https:\/\/doi.org\/10.5582\/bst.2022.01281.","journal-title":"Biosci Trends"},{"issue":"2","key":"1982_CR96","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s12072-020-10101-6","volume":"15","author":"F Fan","year":"2021","unstructured":"Fan F, Chen K, Lu X, Li A, Liu C, Wu B. Dual targeting of PD-l1 and PD-l2 by PCED1b-as1 via sponging hsa-mir-194-5p induces immunosuppression in hepatocellular carcinoma. Hepatol Int. 2021;15(2):444\u201358. https:\/\/doi.org\/10.1007\/s12072-020-10101-6.","journal-title":"Hepatol Int"},{"issue":"1","key":"1982_CR97","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","volume":"22","author":"Z Hu","year":"2023","unstructured":"Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y, et al. Exosome-derived circCCAR1 promotes CD8\u2009+\u2009t-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023;22(1):55. https:\/\/doi.org\/10.1186\/s12943-023-01759-1.","journal-title":"Mol Cancer"},{"key":"1982_CR98","doi-asserted-by":"publisher","first-page":"1144774","DOI":"10.3389\/fimmu.2023.1144774","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Tang A, Cui Y, Gong H, Li H. LRPPRC facilitates tumor progression and immune evasion through upregulation of m(6)a modification of PD-l1 mRNA in hepatocellular carcinoma. Front Immunol. 2023;14:1144774. https:\/\/doi.org\/10.3389\/fimmu.2023.1144774.","journal-title":"Front Immunol"},{"issue":"6","key":"1982_CR99","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s10565-022-09718-0","volume":"38","author":"L Peng","year":"2022","unstructured":"Peng L, Pan B, Zhang X, Wang Z, Qiu J, Wang X, et al. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6a modification of LncRNA MIR155HG to upregulate PD-l1 expression. Cell Biol Toxicol. 2022;38(6):1159\u201373. https:\/\/doi.org\/10.1007\/s10565-022-09718-0.","journal-title":"Cell Biol Toxicol"},{"key":"1982_CR100","doi-asserted-by":"publisher","unstructured":"Xi Q, Yang G, He X, Zhuang H, Li L, Lin B, et al. M6 a-mediated upregulation of LncRNA TUG1 in liver cancer cells regulates the antitumor response of CD8+ t cells and phagocytosis of macrophages. Adv Sci (Weinh). 2024;2400695. https:\/\/doi.org\/10.1002\/advs.202400695.","DOI":"10.1002\/advs.202400695"},{"issue":"13","key":"1982_CR101","doi-asserted-by":"publisher","first-page":"e2307242","DOI":"10.1002\/advs.202307242","volume":"11","author":"J Wen","year":"2024","unstructured":"Wen J, Xue L, Wei Y, Liang J, Jia W, Yong T, et al. YTHDF2 is a therapeutic target for HCC by suppressing immune evasion and angiogenesis through ETV5\/PD-l1\/VEGFA axis. Adv Sci (Weinh). 2024;11(13):e2307242. https:\/\/doi.org\/10.1002\/advs.202307242.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"1982_CR102","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41418-024-01432-0","volume":"32","author":"X Guo","year":"2025","unstructured":"Guo X, Cui T, Sun L, Fu Y, Cheng C, Wu C, et al. A STT3a-dependent PD-l1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma. Cell Death Differ. 2025;32(5):944\u201358. https:\/\/doi.org\/10.1038\/s41418-024-01432-0.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1982_CR103","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/hep4.1682","volume":"6","author":"NN Chui","year":"2022","unstructured":"Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, et al. Inhibition of CMTM4 sensitizes cholangiocarcinoma and hepatocellular carcinoma to t cell-mediated antitumor immunity through PD-l1. Hepatol Commun. 2022;6(1):178\u201393. https:\/\/doi.org\/10.1002\/hep4.1682.","journal-title":"Hepatol Commun"},{"issue":"1","key":"1982_CR104","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00018-024-05144-z","volume":"81","author":"Z Yu","year":"2024","unstructured":"Yu Z, Wu X, Zhu J, Yan H, Li Y, Zhang H, et al. BCLAF1 binds SPOP to stabilize PD-l1 and promotes the development and immune escape of hepatocellular carcinoma. Cell Mol Life Sci. 2024;81(1):82. https:\/\/doi.org\/10.1007\/s00018-024-05144-z.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1982_CR105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41467-023-44466-7","volume":"15","author":"W Ren","year":"2024","unstructured":"Ren W, Xu Z, Chang Y, Ju F, Wu H, Liang Z, et al. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic t cells via degradation of PD-l1. Nat Commun. 2024;15(1):9. https:\/\/doi.org\/10.1038\/s41467-023-44466-7.","journal-title":"Nat Commun"},{"key":"1982_CR106","doi-asserted-by":"publisher","unstructured":"Li Q, Guo W, Qian Y, Li S, Li L, Zhu Z, et al. Protein o-fucosyltransferase 1 promotes PD-l1 stability to drive immune evasion and directs liver cancer to immunotherapy. J Immunother Cancer. 2024;12(6). https:\/\/doi.org\/10.1136\/jitc-2024-008917.","DOI":"10.1136\/jitc-2024-008917"},{"key":"1982_CR107","doi-asserted-by":"publisher","first-page":"115024","DOI":"10.1016\/j.intimp.2025.115024","volume":"161","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Yu Z, Wang J, Wu Y, Li Z, Le T, et al. Targeting USP47 enhances immunotherapy in hepatocellular carcinoma by destabilizing PD-l1. Int Immunopharmacol. 2025;161:115024. https:\/\/doi.org\/10.1016\/j.intimp.2025.115024.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1982_CR108","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41392-021-00784-0","volume":"6","author":"J Chen","year":"2021","unstructured":"Chen J, Lin Z, Liu L, Zhang R, Geng Y, Fan M, et al. GOLM1 exacerbates CD8(+) t cell suppression in hepatocellular carcinoma by promoting Exosomal PD-l1 transport into tumor-associated macrophages. Signal Transduct Target Ther. 2021;6(1):397. https:\/\/doi.org\/10.1038\/s41392-021-00784-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1982_CR109","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40164-024-00476-9","volume":"13","author":"XT Shen","year":"2024","unstructured":"Shen XT, Xie SZ, Zheng X, Zou TT, Hu BY, Xu J, et al. Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma. Exp Hematol Oncol. 2024;13(1):20. https:\/\/doi.org\/10.1186\/s40164-024-00476-9.","journal-title":"Exp Hematol Oncol"},{"key":"1982_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.12.045","author":"G Ye","year":"2025","unstructured":"Ye G, Sun X, Li J, Pu M, Zhang J. Parkin modulates the hepatocellular carcinoma microenvironment by regulating PD-1\/PD-l1 signalling. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2024.12.045.","journal-title":"J Adv Res"},{"key":"1982_CR111","doi-asserted-by":"publisher","unstructured":"Zhang R, Wang J, Du Y, Yu Z, Wang Y, Jiang Y, et al. CDK5 destabilizes PD-l1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. J Immunother Cancer. 2023;11(11). https:\/\/doi.org\/10.1136\/jitc-2023-007529.","DOI":"10.1136\/jitc-2023-007529"},{"key":"1982_CR112","doi-asserted-by":"publisher","first-page":"217901","DOI":"10.1016\/j.canlet.2025.217901","volume":"630","author":"X Wang","year":"2025","unstructured":"Wang X, Li Y, Tang Y, Liu Z, Liu Y, Fu X, et al. PD-l1 delactylation-promoted nuclear translocation accelerates liver cancer growth through elevating SQLE transcription activity. Cancer Lett. 2025;630:217901. https:\/\/doi.org\/10.1016\/j.canlet.2025.217901.","journal-title":"Cancer Lett"},{"issue":"10","key":"1982_CR113","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-024-00828-8","volume":"5","author":"L Lemaitre","year":"2024","unstructured":"Lemaitre L, Adeniji N, Suresh A, Reguram R, Zhang J, Park J, et al. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease. Nat Cancer. 2024;5(10):1534\u201356. https:\/\/doi.org\/10.1038\/s43018-024-00828-8.","journal-title":"Nat Cancer"},{"key":"1982_CR114","doi-asserted-by":"publisher","unstructured":"Jiang D, Huang A, Zhu B, Gong J, Ruan Y, Liu X, et al. Targeting CD93 on monocytes revitalizes antitumor immunity by enhancing the function and infiltration of CD8(+) t cells. J Immunother Cancer. 2024;12(10). https:\/\/doi.org\/10.1136\/jitc-2024-010148.","DOI":"10.1136\/jitc-2024-010148"},{"issue":"1","key":"1982_CR115","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-024-02985-1","volume":"43","author":"X Tu","year":"2024","unstructured":"Tu X, Chen L, Zheng Y, Mu C, Zhang Z, Wang F, et al. S100a9(+)CD14(+) monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating t cell-mediated antitumor function. J Exp Clin Cancer Res. 2024;43(1):72. https:\/\/doi.org\/10.1186\/s13046-024-02985-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"1982_CR116","doi-asserted-by":"publisher","unstructured":"Sung PS, Park DJ, Roh PR, Mun KD, Cho SW, Lee GW, et al. Intrahepatic inflammatory IgA(+)PD-l1(high) monocytes in hepatocellular carcinoma development and immunotherapy. J Immunother Cancer. 2022;10(5). https:\/\/doi.org\/10.1136\/jitc-2021-003618.","DOI":"10.1136\/jitc-2021-003618"},{"issue":"2","key":"1982_CR117","doi-asserted-by":"publisher","first-page":"113651","DOI":"10.1016\/j.yexcr.2023.113651","volume":"428","author":"J Wen","year":"2023","unstructured":"Wen J, Yang S, Yan G, Lei J, Liu X, Zhang N, et al. Increased OIT3 in macrophages promotes PD-l1 expression and hepatocellular carcinogenesis via NF-\u03bab signaling. Exp Cell Res. 2023;428(2):113651. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113651.","journal-title":"Exp Cell Res"},{"key":"1982_CR118","doi-asserted-by":"publisher","first-page":"102463","DOI":"10.1016\/j.redox.2022.102463","volume":"56","author":"X Hao","year":"2022","unstructured":"Hao X, Zheng Z, Liu H, Zhang Y, Kang J, Kong X, et al. Inhibition of APOC1 promotes the transformation of m2 into m1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463. https:\/\/doi.org\/10.1016\/j.redox.2022.102463.","journal-title":"Redox Biol"},{"key":"1982_CR119","doi-asserted-by":"publisher","unstructured":"Sun G, Liu H, Zhao J, Zhang J, Huang T, Sun G, et al. Macrophage GSK3\u03b2-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. J Immunother Cancer. 2022;10(12). https:\/\/doi.org\/10.1136\/jitc-2022-005655.","DOI":"10.1136\/jitc-2022-005655"},{"key":"1982_CR120","doi-asserted-by":"publisher","unstructured":"Petty AJ, Dai R, Lapalombella R, Baiocchi RA, Benson DM, Li Z, et al. Hedgehog-induced PD-l1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8\u2009+\u2009t cell function. JCI Insight. 2021;6(6). https:\/\/doi.org\/10.1172\/jci.insight.146707.","DOI":"10.1172\/jci.insight.146707"},{"issue":"2","key":"1982_CR121","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/CJI.0000000000000496","volume":"47","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pei R, Ding Y, Su Z, Li D, Zhu S, et al. LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1\/PD-l1 axis. J Immunother. 2024;47(2):64\u201376. https:\/\/doi.org\/10.1097\/CJI.0000000000000496.","journal-title":"J Immunother"},{"issue":"2","key":"1982_CR122","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/0008-5472.CAN-24-0954","volume":"85","author":"P Xie","year":"2025","unstructured":"Xie P, Guo L, Yu Q, Zhao Y, Yu M, Wang H, et al. ACE2 enhances sensitivity to PD-l1 Blockade by inhibiting macrophage-induced immunosuppression and angiogenesis. Cancer Res. 2025;85(2):299\u2013313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0954.","journal-title":"Cancer Res"},{"issue":"7","key":"1982_CR123","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","volume":"164","author":"C Zhou","year":"2023","unstructured":"Zhou C, Weng J, Liu C, Liu S, Hu Z, Xie X, et al. Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage m2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma. Gastroenterology. 2023;164(7):1261\u201378. https:\/\/doi.org\/10.1053\/j.gastro.2023.02.005.","journal-title":"Gastroenterology"},{"key":"1982_CR124","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000629","author":"D Yang","year":"2023","unstructured":"Yang D, Tian T, Li X, Zhang B, Qi L, Zhang F, et al. ZNT1 and Zn 2\u2009+\u2009control TLR4 and PD-l1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000629.","journal-title":"Hepatology"},{"issue":"2","key":"1982_CR125","doi-asserted-by":"publisher","first-page":"e2203973","DOI":"10.1002\/advs.202203973","volume":"10","author":"B Tang","year":"2023","unstructured":"Tang B, Zhu J, Wang Y, Chen W, Fang S, Mao W, et al. Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1\/l1 response. Adv Sci (Weinh). 2023;10(2):e2203973. https:\/\/doi.org\/10.1002\/advs.202203973.","journal-title":"Adv Sci (Weinh)"},{"issue":"12","key":"1982_CR126","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1136\/gutjnl-2021-326350","volume":"71","author":"LG Lu","year":"2022","unstructured":"Lu LG, Zhou ZL, Wang XY, Liu BY, Lu JY, Liu S, et al. PD-l1 Blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma. Gut. 2022;71(12):2551\u201360. https:\/\/doi.org\/10.1136\/gutjnl-2021-326350.","journal-title":"Gut"},{"issue":"20","key":"1982_CR127","doi-asserted-by":"publisher","first-page":"e2413095","DOI":"10.1002\/advs.202413095","volume":"12","author":"J Cai","year":"2025","unstructured":"Cai J, Zhang P, Cai Y, Zhu G, Chen S, Song L, et al. Lactylation-driven NUPR1 promotes immunosuppression of tumor-infiltrating macrophages in hepatocellular carcinoma. Adv Sci (Weinh). 2025;12(20):e2413095. https:\/\/doi.org\/10.1002\/advs.202413095.","journal-title":"Adv Sci (Weinh)"},{"key":"1982_CR128","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001244","author":"K Cheng","year":"2025","unstructured":"Cheng K, Cai N, Yang X, Li D, Zhu J, Yang HY, et al. Short-term starvation boosts anti-PD-l1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma. Hepatology. 2025. https:\/\/doi.org\/10.1097\/HEP.0000000000001244.","journal-title":"Hepatology"},{"key":"1982_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.02.009","author":"P Xie","year":"2024","unstructured":"Xie P, Yu M, Zhang B, Yu Q, Zhao Y, Wu M, et al. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.009.","journal-title":"J Hepatol"},{"key":"1982_CR130","doi-asserted-by":"publisher","unstructured":"Deng H, Kan A, Lyu N, He M, Huang X, Qiao S, et al. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-l1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 2021;9(6). https:\/\/doi.org\/10.1136\/jitc-2020-002305.","DOI":"10.1136\/jitc-2020-002305"},{"issue":"1","key":"1982_CR131","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41467-024-46118-w","volume":"15","author":"M He","year":"2024","unstructured":"He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, et al. Serum amyloid a promotes Glycolysis of neutrophils during PD-1 Blockade resistance in hepatocellular carcinoma. Nat Commun. 2024;15(1):1754. https:\/\/doi.org\/10.1038\/s41467-024-46118-w.","journal-title":"Nat Commun"},{"key":"1982_CR132","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000772","author":"JG Park","year":"2024","unstructured":"Park JG, Roh PR, Kang MW, Cho SW, Hwangbo S, Jung HD, et al. Intrahepatic Immunoglobulin a complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of hepatocellular carcinoma. Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000000772.","journal-title":"Hepatology"},{"key":"1982_CR133","doi-asserted-by":"publisher","first-page":"112282","DOI":"10.1016\/j.intimp.2024.112282","volume":"138","author":"H Shang","year":"2024","unstructured":"Shang H, Lu L, Fan M, Lu Y, Shi X, Lu H. Exosomal circHIF1a derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape. Int Immunopharmacol. 2024;138:112282. https:\/\/doi.org\/10.1016\/j.intimp.2024.112282.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1982_CR134","doi-asserted-by":"publisher","first-page":"e2404089","DOI":"10.1002\/advs.202404089","volume":"12","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li X, Chen H, Li J, Guo X, Fang Y, et al. Cancer cell-derived Exosomal mir-500a-3p modulates hepatic stellate cell activation and the immunosuppressive microenvironment. Adv Sci (Weinh). 2025;12(2):e2404089. https:\/\/doi.org\/10.1002\/advs.202404089.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1982_CR135","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park J, Finn RS, Cheng A, Mathurin P, Edeline J, et al. Nivolumab versus Sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1982_CR136","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo B, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202. https:\/\/doi.org\/10.1200\/JCO.19.01307.","journal-title":"J Clin Oncol"},{"issue":"20","key":"1982_CR137","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"issue":"4","key":"1982_CR138","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","volume":"83","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, et al. Five-year overall survival update from the HIMALAYA study of Tremelimumab plus durvalumab in unresectable HCC. J Hepatol. 2025;83(4):899\u2013908. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.033.","journal-title":"J Hepatol"},{"issue":"10474","key":"1982_CR139","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405(10474):203\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3.","journal-title":"Lancet"},{"issue":"8","key":"1982_CR140","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2022-327133","volume":"72","author":"Z Tan","year":"2023","unstructured":"Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, et al. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 Blockade in hepatocellular carcinoma patients. Gut. 2023;72(8):1568\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2022-327133.","journal-title":"Gut"},{"key":"1982_CR141","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10572-3","author":"T Tanaka","year":"2023","unstructured":"Tanaka T, Koga H, Suzuki H, Iwamoto H, Sakaue T, Masuda A, et al. Anti-PD-l1 antibodies promote cellular proliferation by activating the PD-l1-AXL signal relay in liver cancer cells. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10572-3.","journal-title":"Hepatol Int"},{"issue":"8","key":"1982_CR142","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41423-023-01048-3","volume":"20","author":"H Yu","year":"2023","unstructured":"Yu H, Shi T, Yao L, Xu D, Ding Y, Xia Q, et al. Elevated nuclear PIGL disrupts the cmyc\/BRD4 axis and improves PD-1 Blockade therapy by dampening tumor immune evasion. Cell Mol Immunol. 2023;20(8):867\u201380. https:\/\/doi.org\/10.1038\/s41423-023-01048-3.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"1982_CR143","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","volume":"72","author":"Z Xiong","year":"2023","unstructured":"Xiong Z, Chan SL, Zhou J, Vong J, Kwong TT, Zeng X, et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint Blockade in hepatocellular carcinoma. Gut. 2023;72(9):1758\u201373. https:\/\/doi.org\/10.1136\/gutjnl-2022-328364.","journal-title":"Gut"},{"issue":"49","key":"1982_CR144","doi-asserted-by":"publisher","first-page":"eadi2465","DOI":"10.1126\/sciadv.adi2465","volume":"9","author":"W Xiang","year":"2023","unstructured":"Xiang W, Lv H, Xing F, Sun X, Ma Y, Wu L, et al. Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation. Sci Adv. 2023;9(49):eadi2465. https:\/\/doi.org\/10.1126\/sciadv.adi2465.","journal-title":"Sci Adv"},{"key":"1982_CR145","doi-asserted-by":"publisher","unstructured":"Chung YM, Khan PP, Wang H, Tsai WB, Qiao Y, Yu B, et al. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8\u2009+\u2009t cells via Pharmacological activation of FOXO3. J Immunother Cancer. 2021;9(12). https:\/\/doi.org\/10.1136\/jitc-2021-002772.","DOI":"10.1136\/jitc-2021-002772"},{"issue":"2","key":"1982_CR146","doi-asserted-by":"publisher","first-page":"101415","DOI":"10.1016\/j.xcrm.2024.101415","volume":"5","author":"S Wang","year":"2024","unstructured":"Wang S, Zhu L, Li T, Lin X, Zheng Y, Xu D, et al. Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. Cell Rep Med. 2024;5(2):101415. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101415.","journal-title":"Cell Rep Med"},{"key":"1982_CR147","doi-asserted-by":"publisher","first-page":"111799","DOI":"10.1016\/j.intimp.2024.111799","volume":"131","author":"M Yue","year":"2024","unstructured":"Yue M, Li C, Li G. New advances in the study of PD-1\/PD-l1 inhibitors-induced liver injury. Int Immunopharmacol. 2024;131:111799. https:\/\/doi.org\/10.1016\/j.intimp.2024.111799.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1982_CR148","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/jgh.14889","volume":"35","author":"K Sawada","year":"2020","unstructured":"Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. J Gastroenterol Hepatol. 2020;35(6):1042\u20138. https:\/\/doi.org\/10.1111\/jgh.14889.","journal-title":"J Gastroenterol Hepatol"},{"key":"1982_CR149","doi-asserted-by":"publisher","unstructured":"Endo Y, Winarski KL, Sajib MS, Ju A, Wu WJ. Atezolizumab induces necroptosis and contributes to hepatotoxicity of human hepatocytes. Int J Mol Sci. 2023;24(14). https:\/\/doi.org\/10.3390\/ijms241411694.","DOI":"10.3390\/ijms241411694"},{"issue":"2","key":"1982_CR150","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","volume":"73","author":"R Montal","year":"2020","unstructured":"Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabr\u00f3 R, Pinyol R, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73(2):315\u201327. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.008.","journal-title":"J Hepatol"},{"issue":"3","key":"1982_CR151","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/his.13238","volume":"71","author":"D Walter","year":"2017","unstructured":"Walter D, Herrmann E, Schnitzbauer AA, Zeuzem S, Hansmann ML, Peveling-Oberhag J, et al. PD-l1 expression in extrahepatic cholangiocarcinoma. Histopathology. 2017;71(3):383\u201392. https:\/\/doi.org\/10.1111\/his.13238.","journal-title":"Histopathology"},{"issue":"4","key":"1982_CR152","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00262-022-03309-y","volume":"72","author":"LP Mocan","year":"2023","unstructured":"Mocan LP, Craciun R, Grapa C, Melincovici CS, Rusu I, Al HN, et al. PD-l1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. Cancer Immunol Immunother. 2023;72(4):1003\u201314. https:\/\/doi.org\/10.1007\/s00262-022-03309-y.","journal-title":"Cancer Immunol Immunother"},{"key":"1982_CR153","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.2147\/CMAR.S172719","volume":"10","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Wang XY, Zhang Y, Xu D, Dong J, Zhang Z, et al. Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8(+) t-cell immune responses. Cancer Manag Res. 2018;10:4113\u201323. https:\/\/doi.org\/10.2147\/CMAR.S172719.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1982_CR154","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12957-020-02082-5","volume":"18","author":"L Tian","year":"2020","unstructured":"Tian L, Ma J, Ma L, Zheng B, Liu L, Song D, et al. PD-1\/PD-l1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. World J Surg Oncol. 2020;18(1):303. https:\/\/doi.org\/10.1186\/s12957-020-02082-5.","journal-title":"World J Surg Oncol"},{"issue":"10","key":"1982_CR155","doi-asserted-by":"publisher","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, et al. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 Blockade in cholangiocarcinoma. J Clin Invest. 2020;130(10):5380\u201396. https:\/\/doi.org\/10.1172\/JCI137110.","journal-title":"J Clin Invest"},{"key":"1982_CR156","doi-asserted-by":"publisher","first-page":"101954","DOI":"10.1016\/j.tranon.2024.101954","volume":"44","author":"QW Zhang","year":"2024","unstructured":"Zhang QW, Zhu MX, Liu WF, Rui WW, Chen Y, Ding XY, et al. Identification of clinically relevant subsets CD39(+)PD-1(+)CD8(+) t cells and CD39(+) regulatory t cells in intrahepatic cholangiocarcinoma using single-cell cytof. Transl Oncol. 2024;44:101954. https:\/\/doi.org\/10.1016\/j.tranon.2024.101954.","journal-title":"Transl Oncol"},{"issue":"1","key":"1982_CR157","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12935-022-02550-w","volume":"22","author":"Z Gao","year":"2022","unstructured":"Gao Z, Chen JF, Li XG, Shi YH, Tang Z, Liu WR, et al. KRAS acting through ERK signaling stabilizes PD-l1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. Cancer Cell Int. 2022;22(1):128. https:\/\/doi.org\/10.1186\/s12935-022-02550-w.","journal-title":"Cancer Cell Int"},{"key":"1982_CR158","doi-asserted-by":"publisher","first-page":"118068","DOI":"10.1016\/j.lfs.2020.118068","volume":"257","author":"Z Liu","year":"2020","unstructured":"Liu Z, Li S, Zeng J, Zhou X, Li H, Liu X, et al. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-l1. Life Sci. 2020;257:118068. https:\/\/doi.org\/10.1016\/j.lfs.2020.118068.","journal-title":"Life Sci"},{"key":"1982_CR159","doi-asserted-by":"publisher","unstructured":"Liu Z, Zhou K, Zeng J, Zhou X, Li H, Peng K, et al. Liver kinase b1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma. Oncol Rep. 2022;48(3). https:\/\/doi.org\/10.3892\/or.2022.8367.","DOI":"10.3892\/or.2022.8367"},{"key":"1982_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2025.05.001","author":"X Sun","year":"2025","unstructured":"Sun X, Yu B, Yu J, Wang Y, Li X, Sun R, et al. YBX1 is required for maintaining PD-l1 expression in intrahepatic cholangiocarcinoma by regulating STAT1 stability in an m5c-dependent manner. Hepatobiliary Pancreat Dis Int. 2025. https:\/\/doi.org\/10.1016\/j.hbpd.2025.05.001.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"18","key":"1982_CR161","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1158\/0008-5472.CAN-21-0468","volume":"81","author":"X Qiu","year":"2021","unstructured":"Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K, et al. M(6)a demethylase ALKBH5 regulates PD-l1 expression and tumor immunoenvironment in intrahepatic cholangiocarcinoma. Cancer Res. 2021;81(18):4778\u201393. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0468.","journal-title":"Cancer Res"},{"key":"1982_CR162","doi-asserted-by":"publisher","first-page":"845193","DOI":"10.3389\/fimmu.2022.845193","volume":"13","author":"H Zheng","year":"2022","unstructured":"Zheng H, Zheng WJ, Wang ZG, Tao YP, Huang ZP, Yang L, et al. Decreased expression of programmed death ligand-l1 by seven in absentia homolog 2 in cholangiocarcinoma enhances t-cell-mediated antitumor activity. Front Immunol. 2022;13:845193. https:\/\/doi.org\/10.3389\/fimmu.2022.845193.","journal-title":"Front Immunol"},{"issue":"1","key":"1982_CR163","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-024-03006-x","volume":"43","author":"J Li","year":"2024","unstructured":"Li J, Xu X, Xu K, Zhou X, Wu K, Yao Y, et al. N6-methyladenosine-modified circSLCO1b3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-l1. J Exp Clin Cancer Res. 2024;43(1):119. https:\/\/doi.org\/10.1186\/s13046-024-03006-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1982_CR164","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/hep.32387","volume":"76","author":"C Luo","year":"2022","unstructured":"Luo C, Xin H, Zhou Z, Hu Z, Sun R, Yao N, et al. Tumor-derived exosomes induce immunosuppressive macrophages to foster intrahepatic cholangiocarcinoma progression. Hepatology. 2022;76(4):982\u201399. https:\/\/doi.org\/10.1002\/hep.32387.","journal-title":"Hepatology"},{"issue":"6","key":"1982_CR165","doi-asserted-by":"publisher","first-page":"110349","DOI":"10.1016\/j.celrep.2022.110349","volume":"38","author":"L Sun","year":"2022","unstructured":"Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, et al. PD-l1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-\u03b2 receptor i versus II. Cell Rep. 2022;38(6):110349. https:\/\/doi.org\/10.1016\/j.celrep.2022.110349.","journal-title":"Cell Rep"},{"issue":"7777","key":"1982_CR166","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-019-1620-6","volume":"574","author":"AP B\u00e9n\u00e9chet","year":"2019","unstructured":"B\u00e9n\u00e9chet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, et al. Dynamics and genomic landscape of CD8(+) t cells undergoing hepatic priming. Nature. 2019;574(7777):200\u20135. https:\/\/doi.org\/10.1038\/s41586-019-1620-6.","journal-title":"Nature"},{"issue":"2","key":"1982_CR167","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1038\/mtna.2012.63","volume":"2","author":"JS Dolina","year":"2013","unstructured":"Dolina JS, Sung SS, Novobrantseva TI, Nguyen TM, Hahn YS. Lipidoid nanoparticles containing PD-l1 SiRNA delivered in vivo enter Kupffer cells and enhance NK and CD8(+) t cell-mediated hepatic antiviral immunity. Mol Ther Nucleic Acids. 2013;2(2):e72. https:\/\/doi.org\/10.1038\/mtna.2012.63.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"640","key":"1982_CR168","doi-asserted-by":"publisher","first-page":"eabi4670","DOI":"10.1126\/scitranslmed.abi4670","volume":"14","author":"MO Diniz","year":"2022","unstructured":"Diniz MO, Schurich A, Chinnakannan SK, Duriez M, Stegmann KA, Davies J, et al. NK cells limit therapeutic vaccine-induced CD8(+)t cell immunity in a PD-l1-dependent manner. Sci Transl Med. 2022;14(640):eabi4670. https:\/\/doi.org\/10.1126\/scitranslmed.abi4670.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1982_CR169","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00011-010-0233-1","volume":"60","author":"J Chen","year":"2011","unstructured":"Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, et al. Intrahepatic levels of PD-1\/PD-l correlate with liver inflammation in chronic hepatitis b. Inflamm Res. 2011;60(1):47\u201353. https:\/\/doi.org\/10.1007\/s00011-010-0233-1.","journal-title":"Inflamm Res"},{"key":"1982_CR170","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fimmu.2018.00472","volume":"9","author":"YK Yong","year":"2018","unstructured":"Yong YK, Saeidi A, Tan HY, Rosmawati M, Enstr\u00f6m PF, Batran RA, et al. Hyper-expression of PD-1 is associated with the levels of exhausted and dysfunctional phenotypes of Circulating CD161(++)TCR iv\u03b17.2(+) mucosal-associated invariant t cells in chronic hepatitis b virus infection. Front Immunol. 2018;9:472. https:\/\/doi.org\/10.3389\/fimmu.2018.00472.","journal-title":"Front Immunol"},{"issue":"5","key":"1982_CR171","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.immuni.2016.04.008","volume":"44","author":"Y Tian","year":"2016","unstructured":"Tian Y, Kuo CF, Akbari O, Ou JH. Maternal-derived hepatitis b virus e antigen alters macrophage function in offspring to drive viral persistence after vertical transmission. Immunity. 2016;44(5):1204\u201314. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.008.","journal-title":"Immunity"},{"key":"1982_CR172","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ijid.2021.12.325","volume":"115","author":"P Huyen","year":"2022","unstructured":"Huyen P, Dung D, Wei\u00df PJ, Hoan PQ, Giang DP, Uyen NT, et al. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis b infection and related liver disease progression. Int J Infect Dis. 2022;115:229\u201336. https:\/\/doi.org\/10.1016\/j.ijid.2021.12.325.","journal-title":"Int J Infect Dis"},{"key":"1982_CR173","doi-asserted-by":"publisher","first-page":"145935","DOI":"10.1016\/j.gene.2021.145935","volume":"806","author":"HN Xuan","year":"2022","unstructured":"Xuan HN, Thi MHP, Dinh TB, Phuong GD, Tat TN, Tien SB, et al. Association of PD-l1 gene polymorphisms and Circulating sPD-l1 levels with HBV infection susceptibility and related liver disease progression. Gene. 2022;806:145935. https:\/\/doi.org\/10.1016\/j.gene.2021.145935.","journal-title":"Gene"},{"issue":"5","key":"1982_CR174","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/apt.16752","volume":"55","author":"HH Hu","year":"2022","unstructured":"Hu HH, Jeng WJ, Pan MH, Luo WS, Chang CL, Huang YT, et al. Serum soluble programmed cell death 1 levels predict spontaneous functional cure in inactive carriers with chronic hepatitis b. Aliment Pharmacol Ther. 2022;55(5):558\u201367. https:\/\/doi.org\/10.1111\/apt.16752.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"1982_CR175","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1111\/febs.16342","volume":"289","author":"L Yu","year":"2022","unstructured":"Yu L, Guan Y, Li L, Lu N, Zhang C. The transcription factor Eomes promotes expression of inhibitory receptors on hepatic CD8(+) t cells during HBV persistence. FEBS J. 2022;289(11):3241\u201361. https:\/\/doi.org\/10.1111\/febs.16342.","journal-title":"FEBS J"},{"issue":"11","key":"1982_CR176","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1136\/gutjnl-2017-314098","volume":"67","author":"H Li","year":"2018","unstructured":"Li H, Zhai N, Wang Z, Song H, Yang Y, Cui A, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional t cells in chronic HBV infection. Gut. 2018;67(11):2035\u201344. https:\/\/doi.org\/10.1136\/gutjnl-2017-314098.","journal-title":"Gut"},{"issue":"2","key":"1982_CR177","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.immuni.2018.12.024","volume":"50","author":"J Zhou","year":"2019","unstructured":"Zhou J, Peng H, Li K, Qu K, Wang B, Wu Y, et al. Liver-resident NK cells control antiviral activity of hepatic t cells via the PD-1-PD-l1 axis. Immunity. 2019;50(2):403\u201317. https:\/\/doi.org\/10.1016\/j.immuni.2018.12.024.","journal-title":"Immunity"},{"key":"1982_CR178","doi-asserted-by":"publisher","unstructured":"Chang J, Guo Y, Yuan W, Chen Y, Liu B, Li W, et al. HLA-DR\u207a tumor cells show an association with a distinct immune microenvironment and CD8\u207a t-cell exhaustion in HBV-associated hepatocellular carcinoma. Adv Sci (Weinh). 2025;e02979. https:\/\/doi.org\/10.1002\/advs.202502979.","DOI":"10.1002\/advs.202502979"},{"issue":"1","key":"1982_CR179","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41467-018-03584-3","volume":"9","author":"C Sun","year":"2018","unstructured":"Sun C, Lan P, Han Q, Huang M, Zhang Z, Xu G, et al. Oncofetal gene SALL4 reactivation by hepatitis b virus counteracts mir-200c in PD-l1-induced t cell exhaustion. Nat Commun. 2018;9(1):1241. https:\/\/doi.org\/10.1038\/s41467-018-03584-3.","journal-title":"Nat Commun"},{"issue":"1","key":"1982_CR180","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12967-024-05069-y","volume":"22","author":"Y Jia","year":"2024","unstructured":"Jia Y, Zhao J, Wang C, Meng J, Zhao L, Yang H, et al. HBV DNA polymerase upregulates the transcription of PD-l1 and suppresses t cell activity in hepatocellular carcinoma. J Transl Med. 2024;22(1):272. https:\/\/doi.org\/10.1186\/s12967-024-05069-y.","journal-title":"J Transl Med"},{"issue":"1","key":"1982_CR181","doi-asserted-by":"publisher","first-page":"G162","DOI":"10.1152\/ajpgi.00197.2019","volume":"318","author":"Y Sun","year":"2020","unstructured":"Sun Y, Yu M, Qu M, Ma Y, Zheng D, Yue Y, et al. Hepatitis b virus-triggered PTEN\/\u03b2-catenin\/c-myc signaling enhances PD-l1 expression to promote immune evasion. Am J Physiol Gastrointest Liver Physiol. 2020;318(1):G162\u201373. https:\/\/doi.org\/10.1152\/ajpgi.00197.2019.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"1982_CR182","doi-asserted-by":"publisher","first-page":"109533","DOI":"10.1016\/j.isci.2024.109533","volume":"27","author":"R Deng","year":"2024","unstructured":"Deng R, Tian R, Li X, Xu Y, Li Y, Wang X, et al. ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21\/AKT\/\u03b2-catenin\/PD-l1 axis. iScience. 2024;27(4):109533. https:\/\/doi.org\/10.1016\/j.isci.2024.109533.","journal-title":"iScience"},{"issue":"5","key":"1982_CR183","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/labmed\/lmaa110","volume":"52","author":"W Liu","year":"2021","unstructured":"Liu W, Zheng X, Wang J, He Q, Li J, Zhang Z, et al. MicroRNA-138 regulates t-cell function by targeting PD-1 in patients with hepatitis b virus-related liver diseases. Lab Med. 2021;52(5):439\u201351. https:\/\/doi.org\/10.1093\/labmed\/lmaa110.","journal-title":"Lab Med"},{"issue":"8","key":"1982_CR184","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/intimm\/dxaa018","volume":"32","author":"Y Yamamoto","year":"2020","unstructured":"Yamamoto Y, Kakizaki M, Shimizu T, Carreras J, Chiba T, Chamoto K, et al. PD-l1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. Int Immunol. 2020;32(8):519\u201331. https:\/\/doi.org\/10.1093\/intimm\/dxaa018.","journal-title":"Int Immunol"},{"issue":"1","key":"1982_CR185","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13046-023-02710-4","volume":"42","author":"L Liu","year":"2023","unstructured":"Liu L, Liu J, Li P, Luo J, Qin R, Peng Q, et al. Single-cell analysis reveals HBV-specific PD-1(+)CD8(+) TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients. J Exp Clin Cancer Res. 2023;42(1):152. https:\/\/doi.org\/10.1186\/s13046-023-02710-4.","journal-title":"J Exp Clin Cancer Res"},{"key":"1982_CR186","doi-asserted-by":"publisher","first-page":"1330644","DOI":"10.3389\/fimmu.2024.1330644","volume":"15","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Huang J, Pang J, Pan S, Wu Y, Jie Y, et al. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy. Front Immunol. 2024;15:1330644. https:\/\/doi.org\/10.3389\/fimmu.2024.1330644.","journal-title":"Front Immunol"},{"issue":"1","key":"1982_CR187","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","volume":"82","author":"H Mon","year":"2025","unstructured":"Mon H, Lee P, Hung Y, Hung Y, Wu C, Lee C, et al. Functional cure of hepatitis b in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2025;82(1):51\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.018.","journal-title":"J Hepatol"},{"key":"1982_CR188","doi-asserted-by":"publisher","unstructured":"Chen Z, Chen Y, Peng L, Wang X, Tang N. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-l1. J Immunother Cancer. 2020;8(2). https:\/\/doi.org\/10.1136\/jitc-2020-001377.","DOI":"10.1136\/jitc-2020-001377"},{"issue":"2","key":"1982_CR189","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2023.02.040","volume":"80","author":"A Cui","year":"2024","unstructured":"Cui A, Li B, Wallace MS, Gonye A, Oetheimer C, Patel H, et al. Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis. J Hepatol. 2024;80(2):251\u201367. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.040.","journal-title":"J Hepatol"},{"issue":"1","key":"1982_CR190","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1053\/j.gastro.2009.09.009","volume":"138","author":"Z Tu","year":"2010","unstructured":"Tu Z, Pierce RH, Kurtis J, Kuroki Y, Crispe IN, Orloff MS. Hepatitis c virus core protein subverts the antiviral activities of human Kupffer cells. Gastroenterology. 2010;138(1):305\u201314. https:\/\/doi.org\/10.1053\/j.gastro.2009.09.009.","journal-title":"Gastroenterology"},{"issue":"23","key":"1982_CR191","doi-asserted-by":"publisher","first-page":"e2300644","DOI":"10.1002\/advs.202300644","volume":"10","author":"LT Wang","year":"2023","unstructured":"Wang LT, Wang SN, Chiou SS, Tsai JP, Chai CY, Tseng LW, et al. HCV core protein-ISX axis promotes chronic liver disease progression via metabolic remodeling and immune suppression. Adv Sci (Weinh). 2023;10(23):e2300644. https:\/\/doi.org\/10.1002\/advs.202300644.","journal-title":"Adv Sci (Weinh)"},{"key":"1982_CR192","doi-asserted-by":"publisher","unstructured":"Pipitone RM, Lupo G, Zito R, Javed A, Petta S, Pennisi G, et al. The PD-1\/PD-l1 axis in the biology of MASLD. Int J Mol Sci. 2024;25(7). https:\/\/doi.org\/10.3390\/ijms25073671.","DOI":"10.3390\/ijms25073671"},{"issue":"3","key":"1982_CR193","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/liv.14336","volume":"40","author":"LA Orci","year":"2020","unstructured":"Orci LA, Kreutzfeldt M, Goossens N, Rubbia-Brandt L, Slits F, Hammad K, et al. Tolerogenic properties of liver macrophages in non-alcoholic steatohepatitis. Liver Int. 2020;40(3):609\u201321. https:\/\/doi.org\/10.1111\/liv.14336.","journal-title":"Liver Int"},{"key":"1982_CR194","doi-asserted-by":"publisher","first-page":"603133","DOI":"10.3389\/fimmu.2021.603133","volume":"12","author":"Y Sakamoto","year":"2021","unstructured":"Sakamoto Y, Yoshio S, Doi H, Mori T, Matsuda M, Kawai H, et al. Increased frequency of dysfunctional siglec-7(-)CD57(+)PD-1(+) natural killer cells in patients with non-alcoholic fatty liver disease. Front Immunol. 2021;12:603133. https:\/\/doi.org\/10.3389\/fimmu.2021.603133.","journal-title":"Front Immunol"},{"key":"1982_CR195","doi-asserted-by":"publisher","first-page":"5954437","DOI":"10.1155\/2022\/5954437","volume":"2022","author":"G Dong","year":"2022","unstructured":"Dong G, Huang X, Chen R, Wu L, Jiang S, Chen S. Increased PD-l1 restricts liver injury in nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2022;2022:5954437. https:\/\/doi.org\/10.1155\/2022\/5954437.","journal-title":"Oxid Med Cell Longev"},{"key":"1982_CR196","doi-asserted-by":"publisher","unstructured":"Zhang Z, Liao Q, Pan T, Yu L, Luo Z, Su S, et al. BATF relieves hepatic steatosis by inhibiting PD1 and promoting energy metabolism. Elife. 2023;12. https:\/\/doi.org\/10.7554\/eLife.88521.","DOI":"10.7554\/eLife.88521"},{"issue":"3","key":"1982_CR197","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","volume":"77","author":"S Wabitsch","year":"2022","unstructured":"Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, et al. Metformin treatment rescues CD8(+) t-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol. 2022;77(3):748\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.010.","journal-title":"J Hepatol"},{"issue":"3","key":"1982_CR198","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/HEP.0000000000000591","volume":"79","author":"M Li","year":"2024","unstructured":"Li M, Wang L, Cong L, Wong CC, Zhang X, Chen H, et al. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology. 2024;79(3):560\u201374. https:\/\/doi.org\/10.1097\/HEP.0000000000000591.","journal-title":"Hepatology"},{"issue":"1","key":"1982_CR199","doi-asserted-by":"publisher","first-page":"2184991","DOI":"10.1080\/2162402X.2023.2184991","volume":"12","author":"S Lacotte","year":"2023","unstructured":"Lacotte S, Slits F, Moeckli B, Peloso A, Koenig S, Tihy M, et al. Anti-CD122 antibody restores specific CD8(+) t cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth. Oncoimmunology. 2023;12(1):2184991. https:\/\/doi.org\/10.1080\/2162402X.2023.2184991.","journal-title":"Oncoimmunology"},{"issue":"7854","key":"1982_CR200","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136. https:\/\/doi.org\/10.1038\/s41586-021-03362-0.","journal-title":"Nature"},{"issue":"8","key":"1982_CR201","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1111\/liv.15586","volume":"43","author":"RM Pipitone","year":"2023","unstructured":"Pipitone RM, Malvestiti F, Pennisi G, Jamialahmadi O, Dongiovanni P, Bertolazzi G, et al. Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease. Liver Int. 2023;43(8):1761\u201371. https:\/\/doi.org\/10.1111\/liv.15586.","journal-title":"Liver Int"},{"key":"1982_CR202","doi-asserted-by":"publisher","unstructured":"Eldafashi N, Darlay R, Shukla R, McCain MV, Watson R, Liu YL, et al. A PDCD1 role in the genetic predisposition to NAFLD-HCC? Cancers (Basel). 2021;13(6). https:\/\/doi.org\/10.3390\/cancers13061412.","DOI":"10.3390\/cancers13061412"},{"issue":"2","key":"1982_CR203","doi-asserted-by":"publisher","first-page":"G237","DOI":"10.1152\/ajpgi.00371.2015","volume":"311","author":"F Wang","year":"2016","unstructured":"Wang F, Huang X, Chung CS, Chen Y, Hutchins NA, Ayala A. Contribution of programmed cell death receptor (PD)-1 to Kupffer cell dysfunction in murine polymicrobial sepsis. Am J Physiol Gastrointest Liver Physiol. 2016;311(2):G237\u201345. https:\/\/doi.org\/10.1152\/ajpgi.00371.2015.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1982_CR204","doi-asserted-by":"publisher","unstructured":"Triantafyllou E, Gudd CL, Mawhin MA, Husbyn HC, Trovato FM, Siggins MK, et al. PD-1 Blockade improves Kupffer cell bacterial clearance in acute liver injury. J Clin Invest. 2021;131(4). https:\/\/doi.org\/10.1172\/JCI140196.","DOI":"10.1172\/JCI140196"},{"issue":"5","key":"1982_CR205","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1189\/jlb.0113051","volume":"94","author":"NA Hutchins","year":"2013","unstructured":"Hutchins NA, Wang F, Wang Y, Chung CS, Ayala A. Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. J Leukoc Biol. 2013;94(5):963\u201370. https:\/\/doi.org\/10.1189\/jlb.0113051.","journal-title":"J Leukoc Biol"},{"key":"1982_CR206","doi-asserted-by":"publisher","first-page":"620365","DOI":"10.3389\/fimmu.2021.620365","volume":"12","author":"W Wu","year":"2021","unstructured":"Wu W, Sun S, Wang Y, Zhao R, Ren H, Li Z, et al. Circulating neutrophil dysfunction in HBV-related acute-on-chronic liver failure. Front Immunol. 2021;12:620365. https:\/\/doi.org\/10.3389\/fimmu.2021.620365.","journal-title":"Front Immunol"},{"key":"1982_CR207","doi-asserted-by":"publisher","first-page":"1041176","DOI":"10.3389\/fimmu.2022.1041176","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, He W, Wang C, Cui N, Yang C, You Z, et al. Characterization of intrahepatic b cells in acute-on-chronic liver failure. Front Immunol. 2022;13:1041176. https:\/\/doi.org\/10.3389\/fimmu.2022.1041176.","journal-title":"Front Immunol"},{"issue":"4","key":"1982_CR208","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jhep.2015.11.021","volume":"64","author":"H Gr\u00f8nb\u00e6k","year":"2016","unstructured":"Gr\u00f8nb\u00e6k H, R\u00f8dgaard-Hansen S, Aagaard NK, Arroyo V, Moestrup SK, Garcia E, et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol. 2016;64(4):813\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.021.","journal-title":"J Hepatol"},{"issue":"3","key":"1982_CR209","doi-asserted-by":"publisher","first-page":"283","DOI":"10.14218\/JCTH.2020.00142","volume":"9","author":"X Zhou","year":"2021","unstructured":"Zhou X, Li Y, Ji Y, Liu T, Zhao N, He J, et al. PD-1 involvement in peripheral blood CD8(+) t lymphocyte dysfunction in patients with acute-on-chronic liver failure. J Clin Transl Hepatol. 2021;9(3):283\u201390. https:\/\/doi.org\/10.14218\/JCTH.2020.00142.","journal-title":"J Clin Transl Hepatol"},{"key":"1982_CR210","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ebiom.2019.10.011","volume":"49","author":"F Leboss\u00e9","year":"2019","unstructured":"Leboss\u00e9 F, Gudd C, Tunc E, Singanayagam A, Nathwani R, Triantafyllou E, et al. CD8(+)t cells from patients with cirrhosis display a phenotype that May contribute to cirrhosis-associated immune dysfunction. EBioMedicine. 2019;49:258\u201368. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.011.","journal-title":"EBioMedicine"},{"issue":"1","key":"1982_CR211","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.31644","volume":"74","author":"E Pose","year":"2021","unstructured":"Pose E, Coll M, Mart\u00ednez-S\u00e1nchez C, Zeng Z, Surewaard B, Catal\u00e0 C, et al. Programmed death ligand 1 is overexpressed in liver macrophages in chronic liver diseases, and its Blockade improves the antibacterial activity against infections. Hepatology. 2021;74(1):296\u2013311. https:\/\/doi.org\/10.1002\/hep.31644.","journal-title":"Hepatology"},{"issue":"4","key":"1982_CR212","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1053\/j.gastro.2008.06.042","volume":"135","author":"M Kido","year":"2008","unstructured":"Kido M, Watanabe N, Okazaki T, Akamatsu T, Tanaka J, Saga K, et al. Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory t cells and PD-1-mediated signaling. Gastroenterology. 2008;135(4):1333\u201343. https:\/\/doi.org\/10.1053\/j.gastro.2008.06.042.","journal-title":"Gastroenterology"},{"issue":"1","key":"1982_CR213","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s40001-023-01419-6","volume":"28","author":"X Gao","year":"2023","unstructured":"Gao X, Wang X, Guan Y, Wang L, Gao Y, Niu J. Soluble immune checkpoints are elevated in patients with primary biliary cholangitis. Eur J Med Res. 2023;28(1):477. https:\/\/doi.org\/10.1186\/s40001-023-01419-6.","journal-title":"Eur J Med Res"},{"issue":"2","key":"1982_CR214","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1572-0241.2006.00948.x","volume":"102","author":"N Mataki","year":"2007","unstructured":"Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y, Kurihara C, et al. Expression of PD-1, PD-l1, and PD-l2 in the liver in autoimmune liver diseases. Am J Gastroenterol. 2007;102(2):302\u201312. https:\/\/doi.org\/10.1111\/j.1572-0241.2006.00948.x.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1982_CR215","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2020.05.053","volume":"73","author":"A Renand","year":"2020","unstructured":"Renand A, Cervera-Marzal I, Gil L, Dong C, Garcia A, Kervagoret E, et al. Integrative molecular profiling of autoreactive CD4 t cells in autoimmune hepatitis. J Hepatol. 2020;73(6):1379\u201390. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.053.","journal-title":"J Hepatol"},{"issue":"7","key":"1982_CR216","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s10620-021-07165-1","volume":"67","author":"S Zhang","year":"2022","unstructured":"Zhang S, Tao X, Wang L, Chen H, Zhao L, Sun J, et al. Downregulation of programmed death-1 pathway promoting CD8\u2009+\u2009t cell cytotoxicity in primary biliary cholangitis. Dig Dis Sci. 2022;67(7):2981\u201393. https:\/\/doi.org\/10.1007\/s10620-021-07165-1.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1982_CR217","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jhep.2020.10.035","volume":"74","author":"S Stein","year":"2021","unstructured":"Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, et al. IL-17a\/f enable cholangiocytes to restrict t cell-driven experimental cholangitis by upregulating PD-l1 expression. J Hepatol. 2021;74(4):919\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2020.10.035.","journal-title":"J Hepatol"},{"issue":"1","key":"1982_CR218","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1038\/s41467-024-46654-5","volume":"15","author":"HX Zhu","year":"2024","unstructured":"Zhu HX, Yang SH, Gao CY, Bian ZH, Chen XM, Huang RR, et al. Targeting pathogenic CD8(+) tissue-resident t cells with chimeric antigen receptor therapy in murine autoimmune cholangitis. Nat Commun. 2024;15(1):2936. https:\/\/doi.org\/10.1038\/s41467-024-46654-5.","journal-title":"Nat Commun"},{"issue":"9","key":"1982_CR219","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/hep4.1226","volume":"2","author":"L Adam","year":"2018","unstructured":"Adam L, Zoldan K, Hofmann M, Schultheiss M, Bettinger D, Neumann-Haefelin C, et al. Follicular t helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis. Hepatol Commun. 2018;2(9):1051\u201363. https:\/\/doi.org\/10.1002\/hep4.1226.","journal-title":"Hepatol Commun"},{"issue":"30","key":"1982_CR220","doi-asserted-by":"publisher","first-page":"28588","DOI":"10.18632\/oncotarget.5665","volume":"6","author":"AR Concepcion","year":"2015","unstructured":"Concepcion AR, Salas JT, S\u00e1ez E, Sarvide S, Ferrer A, Portu A, et al. CD8\u2009+\u2009t cells undergo activation and programmed death-1 repression in the liver of aged ae2a,b-\/- mice favoring autoimmune cholangitis. Oncotarget. 2015;6(30):28588\u2013606. https:\/\/doi.org\/10.18632\/oncotarget.5665.","journal-title":"Oncotarget"},{"key":"1982_CR221","doi-asserted-by":"publisher","first-page":"1326078","DOI":"10.3389\/fimmu.2023.1326078","volume":"14","author":"L Kocheise","year":"2023","unstructured":"Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, et al. PD-1\/PD-l1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Front Immunol. 2023;14:1326078. https:\/\/doi.org\/10.3389\/fimmu.2023.1326078.","journal-title":"Front Immunol"},{"issue":"11","key":"1982_CR222","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.7150\/thno.107418","volume":"15","author":"J Deng","year":"2025","unstructured":"Deng J, Zhu J, Jiang X, Yao C, Chen H, Ding Y, et al. PD-1 activation mitigates lupus nephritis by suppressing hyperactive and heterogeneous PD-1(+)CD8(+) t cells. Theranostics. 2025;15(11):5029\u201344. https:\/\/doi.org\/10.7150\/thno.107418.","journal-title":"Theranostics"},{"issue":"1","key":"1982_CR223","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13287-025-04347-w","volume":"16","author":"X Bai","year":"2025","unstructured":"Bai X, Liu T, Li C, Qiu C, Ge X, Gou H, et al. PD-l1 and ICAM1 over expression empowers immunoregulation of mesenchymal stromal cells to improve the autoimmune hepatitis treatment efficacy. Stem Cell Res Ther. 2025;16(1):209. https:\/\/doi.org\/10.1186\/s13287-025-04347-w.","journal-title":"Stem Cell Res Ther"},{"issue":"8062","key":"1982_CR224","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-025-08717-5","volume":"641","author":"Y Shen","year":"2025","unstructured":"Shen Y, Bai X, Zhang Q, Liang X, Jin X, Zhao Z, et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature. 2025;641(8062):503\u201311. https:\/\/doi.org\/10.1038\/s41586-025-08717-5.","journal-title":"Nature"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01982-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01982-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:30:48Z","timestamp":1767677448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01982-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":224,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01982-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"87"}}